^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

1914 Gain of chr1q Portends Poor Outcomes in Multiple Myeloma Patients Treated with Venetoclax

Published date:
11/03/2022
Excerpt:
In this study, we sought to investigate the genomic determinants of response to venetoclax in a real-world setting outside of clinical trials....Our analysis showed a trend towards higher expression of BCL2 (p=0.07) and the BCL2/MCL1 ratio (p=0.07), as well as significant up-regulation of the BCL2/BCL2L1 ratio in patients with higher PFS (p<0.05).
DOI:
https://doi.org/10.1182/blood-2022-166572